MYCN and lung cancer: Importantly, miR-34a modulates the p53/miR-34a/MYCN pathway to enhance the effectiveness of cisplatin therapy in lung cancer [6], whereas miR-497-5p enhances the cisplatin sensitivity of lung cancer cells by inhibiting Yes-associated protein 1 (YAP1) and TEA domain family member 1 (TEAD1), key components of the Hippo pathway [42].